Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...
Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...
Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and ...
It is unknown if Tezspire (tezepelumab-ekko) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...
The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...
(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also ...
6d
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback